Tapewire

Nasdaq · USD

RGEN

REPLIGEN CORP

Export transactions ↓
Tapewire entity
486
SEC CIK
0000730272
Parsed reports
388

Last 12 months

Inside the activity.

0 purchase rows · 25 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025014
Dec 202501
Jan 202600
Feb 202600
Mar 202600
Apr 202601
May 202600
Jun 202601
Jul 202601
Aug 202601
Sep 202604
Oct 202602

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 06, 2026 Filed Oct 8, 2026 20:40 UTC
Douglass Brian RobbCHIEF PRODUCT OFFICER
GrantStock Option (Right to Buy) · Derivative 675 $0.00 Strike: $174.86 $0.00
Disclosure

SEC source: 0001628280-26-065462 · wk-form4_1791492005.xml · derivative · entry 2

Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 675

Underlying: Common Stock · 675 shares

Expires 2036-10-06

F2 · derivative.exercise_date: 225 shares will vest on each of October 6, 2027, October 6, 2028, and October 6, 2029.

Read SEC document
October 06, 2026 Filed Oct 8, 2026 20:40 UTC
Douglass Brian RobbCHIEF PRODUCT OFFICER
GrantCommon Stock 700 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-065462 · wk-form4_1791492005.xml · nonDerivative · entry 1

Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,685

F1 · shares: Mr. Douglass was awarded 700 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
October 05, 2026 Filed Oct 6, 2026 20:18 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 4,202 $0.00 Strike: $154.96 $0.00
Disclosure

SEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · derivative · entry 4

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,405

Underlying: Common Stock · 4,202 shares

Expires 2033-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F2 · derivative.exercise_date: 4,202 shares will vest on October 2, 2027. 4,203 shares will vest on October 2, 2028.

Read SEC document
October 05, 2026 Filed Oct 6, 2026 20:18 UTC
Loeillot OlivierDirector · Chief Executive Officer
SaleCommon Stock 4,202 $190.00 $798,380.00
Disclosure

SEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 3

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
October 05, 2026 Filed Oct 6, 2026 20:18 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionCommon Stock 4,202 $154.96 $651,141.92
Disclosure

SEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
October 05, 2026 Filed Oct 6, 2026 20:18 UTC
Loeillot OlivierDirector · Chief Executive Officer
SaleCommon Stock 1,333 $178.75 $238,273.75
Disclosure

SEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
October 02, 2026 Filed Oct 5, 2026 20:01 UTC
Loeillot OlivierDirector · Chief Executive Officer
Tax withholdingCommon Stock 1,248 $181.70 $226,761.60
Disclosure

SEC source: 0001628280-26-064889 · wk-form4_1791230479.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,121

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
September 25, 2026 Filed Sep 28, 2026 20:05 UTC Tax withholdingCommon Stock 421 $189.68 $79,855.28
Disclosure

SEC source: 0001628280-26-063714 · wk-form4_1790625949.xml · nonDerivative · entry 1

Garland Jason K · CIK 0001754555 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,408

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 4,542 $0.00 Strike: $155.38 $0.00
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · derivative · entry 6

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,085

Underlying: Common Stock · 4,542 shares

Expires 2035-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F3 · derivative.exercise_date: 4,542 shares will vest on March 1, 2027, and 4,543 shares will vest on March 1, 2028.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 8,404 $0.00 Strike: $154.96 $0.00
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · derivative · entry 5

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,607

Underlying: Common Stock · 8,404 shares

Expires 2033-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F2 · derivative.exercise_date: 4,202 shares will vest on each of October 2, 2026, and October 2, 2027. 4,203 shares will vest on October 2, 2028.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC
Loeillot OlivierDirector · Chief Executive Officer
SaleCommon Stock 4,542 $190.00 $862,980.00
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 4

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionCommon Stock 4,542 $155.38 $705,735.96
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 3

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC
Loeillot OlivierDirector · Chief Executive Officer
SaleCommon Stock 8,404 $190.00 $1,596,760.00
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 24, 2026 Filed Sep 25, 2026 20:09 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionCommon Stock 8,404 $154.96 $1,302,283.84
Disclosure

SEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 21, 2026 Filed Sep 22, 2026 20:07 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 5,426 $0.00 Strike: $141.79 $0.00
Disclosure

SEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · derivative · entry 3

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,426

Underlying: Common Stock · 5,426 shares

Expires 2034-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 21, 2026 Filed Sep 22, 2026 20:07 UTC
Loeillot OlivierDirector · Chief Executive Officer
SaleCommon Stock 5,426 $180.00 $976,680.00
Disclosure

SEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,369

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 21, 2026 Filed Sep 22, 2026 20:07 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionCommon Stock 5,426 $141.79 $769,352.54
Disclosure

SEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 04, 2026 Filed Sep 8, 2026 20:13 UTC
Loeillot OlivierDirector · Chief Executive Officer
SaleCommon Stock 3,035 $165.90 $503,506.50
Disclosure

SEC source: 0001628280-26-060911 · wk-form4_1788898417.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,369

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
September 03, 2026 Filed Sep 8, 2026 20:13 UTC
Loeillot OlivierDirector · Chief Executive Officer
Tax withholdingCommon Stock 2,842 $169.61 $482,031.62
Disclosure

SEC source: 0001628280-26-060911 · wk-form4_1788898417.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,404

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
September 01, 2026 Filed Sep 2, 2026 20:18 UTC
Hughes ViolettaCHIEF ACCOUNTING OFFICER
Tax withholdingCommon Stock 277 $170.02 $47,095.54
Disclosure

SEC source: 0001628280-26-060105 · wk-form4_1788380307.xml · nonDerivative · entry 2

Hughes Violetta · CIK 0001991429 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,331

F2 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
August 20, 2026 Filed Aug 21, 2026 20:06 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 5,426 $0.00 Strike: $141.79 $0.00
Disclosure

SEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · derivative · entry 3

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,852

Underlying: Common Stock · 5,426 shares

Expires 2034-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

F2 · derivative.exercise_date: 5,426 shares will vest on each of September 3, 2026, and September 3, 2027.

Read SEC document
August 20, 2026 Filed Aug 21, 2026 20:06 UTC
Loeillot OlivierDirector · Chief Executive Officer
SaleCommon Stock 5,426 $180.00 $976,680.00
Disclosure

SEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · nonDerivative · entry 2

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,246

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
August 20, 2026 Filed Aug 21, 2026 20:06 UTC
Loeillot OlivierDirector · Chief Executive Officer
Exercise / conversionCommon Stock 5,426 $141.79 $769,352.54
Disclosure

SEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,672

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Read SEC document
July 16, 2026 Filed Jul 17, 2026 20:40 UTC SaleCommon Stock 530 $150.00 $79,500.00
Disclosure

SEC source: 0001193125-26-307925 · ownership.xml · nonDerivative · entry 1

Garland Jason K · CIK 0001754555 · CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,829

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025.

Read SEC document
June 25, 2026 Filed Jun 26, 2026 20:05 UTC SaleCommon Stock 733 $145.00 $106,285.00
Disclosure

SEC source: 0001193125-26-285449 · ownership.xml · nonDerivative · entry 1

Garland Jason K · CIK 0001754555 · CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,359

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantStock Option (Right to Buy) · Derivative 2,239 $0.00 Strike: $103.38 $0.00
Disclosure

SEC source: 0001193125-26-228896 · ownership.xml · derivative · entry 4

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,239

Underlying: Common Stock · 2,239 shares

Expires 2036-05-14

F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantCommon Stock 995 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-228896 · ownership.xml · nonDerivative · entry 1

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,581

F1 · shares: Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantStock Option (Right to Buy) · Derivative 2,239 $0.00 Strike: $103.38 $0.00
Disclosure

SEC source: 0001193125-26-228897 · ownership.xml · derivative · entry 2

Konstantinov Konstantin · CIK 0001774649 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,239

Underlying: Common Stock · 2,239 shares

Expires 2036-05-14

F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantCommon Stock 995 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-228897 · ownership.xml · nonDerivative · entry 1

Konstantinov Konstantin · CIK 0001774649 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,889

F1 · shares: Mr. Konstantinov was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantStock Option (Right to Buy) · Derivative 2,239 $0.00 Strike: $103.38 $0.00
Disclosure

SEC source: 0001193125-26-228893 · ownership.xml · derivative · entry 2

EGLINTON MANNER CARRIE · CIK 0001696776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,239

Underlying: Common Stock · 2,239 shares

Expires 2036-05-14

F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantCommon Stock 995 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-228893 · ownership.xml · nonDerivative · entry 1

EGLINTON MANNER CARRIE · CIK 0001696776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,461

F1 · shares: Ms. Manner was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC
Mhatre RohinDirector
GrantStock Option (Right to Buy) · Derivative 2,239 $0.00 Strike: $103.38 $0.00
Disclosure

SEC source: 0001193125-26-228888 · ownership.xml · derivative · entry 2

Mhatre Rohin · CIK 0001798735 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,239

Underlying: Common Stock · 2,239 shares

Expires 2036-05-14

F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC
Mhatre RohinDirector
GrantCommon Stock 995 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-228888 · ownership.xml · nonDerivative · entry 1

Mhatre Rohin · CIK 0001798735 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,014

F1 · shares: Mr. Mhatre was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC
Pax MargaretDirector
GrantStock Option (Right to Buy) · Derivative 2,239 $0.00 Strike: $103.38 $0.00
Disclosure

SEC source: 0001193125-26-228886 · ownership.xml · derivative · entry 2

Pax Margaret · CIK 0001999772 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,239

Underlying: Common Stock · 2,239 shares

Expires 2036-05-14

F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC
Pax MargaretDirector
GrantCommon Stock 995 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-228886 · ownership.xml · nonDerivative · entry 1

Pax Margaret · CIK 0001999772 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,011

F1 · shares: Ms. Pax was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC
MUIR GLENN PDirector
GrantStock Option (Right to Buy) · Derivative 2,239 $0.00 Strike: $103.38 $0.00
Disclosure

SEC source: 0001193125-26-228891 · ownership.xml · derivative · entry 2

MUIR GLENN P · CIK 0001181190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,239

Underlying: Common Stock · 2,239 shares

Expires 2036-05-14

F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC
MUIR GLENN PDirector
GrantCommon Stock 995 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-228891 · ownership.xml · nonDerivative · entry 1

MUIR GLENN P · CIK 0001181190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,051

F1 · shares: Mr. Muir was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantStock Option (Right to Buy) · Derivative 2,239 $0.00 Strike: $103.38 $0.00
Disclosure

SEC source: 0001193125-26-228884 · ownership.xml · derivative · entry 2

DAWES KAREN A · CIK 0001261506 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,239

Underlying: Common Stock · 2,239 shares

Expires 2036-05-14

F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantCommon Stock 995 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-228884 · ownership.xml · nonDerivative · entry 1

DAWES KAREN A · CIK 0001261506 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,816

F1 · shares: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantStock Option (Right to Buy) · Derivative 2,239 $0.00 Strike: $103.38 $0.00
Disclosure

SEC source: 0001193125-26-228883 · ownership.xml · derivative · entry 2

BARTHELEMY NICOLAS · CIK 0001283576 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,239

Underlying: Common Stock · 2,239 shares

Expires 2036-05-14

F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC GrantCommon Stock 995 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-228883 · ownership.xml · nonDerivative · entry 1

BARTHELEMY NICOLAS · CIK 0001283576 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,436

F1 · shares: Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
May 07, 2026 Filed May 8, 2026 18:48 UTC
MUIR GLENN PDirector
Exercise / conversionStock Option (Right to Buy) · Derivative 2,434 $0.00 Strike: $38.76 $0.00
Disclosure

SEC source: 0001193125-26-214293 · ownership.xml · derivative · entry 2

MUIR GLENN P · CIK 0001181190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,434

Underlying: Common Stock · 2,434 shares

Expires 2027-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
May 07, 2026 Filed May 8, 2026 18:48 UTC
MUIR GLENN PDirector
Exercise / conversionCommon Stock 2,434 $38.76 $94,341.84
Disclosure

SEC source: 0001193125-26-214293 · ownership.xml · nonDerivative · entry 1

MUIR GLENN P · CIK 0001181190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,056

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 07, 2026 Filed May 8, 2026 18:39 UTC
Douglass Brian RobbCHIEF PRODUCT OFFICER
Tax withholdingCommon Stock 334 $126.43 $42,227.62
Disclosure

SEC source: 0001193125-26-214265 · ownership.xml · nonDerivative · entry 1

Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,985

F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
April 21, 2026 Filed Apr 22, 2026 17:26 UTC
Loeillot OlivierDirector · Chief Executive Officer
SaleCommon Stock 3,832 $140.00 $536,480.00
Disclosure

SEC source: 0001193125-26-169682 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,246

F1 · price: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on August 19th, 2025.

Read SEC document
March 05, 2026 Filed Mar 23, 2026 16:00 UTC
KURIYEL RALFSenior VP, R&D
GrantStock Option (Right to Buy) · Derivative 5,669 $0.00 Strike: $141.91 $0.00
Disclosure

SEC source: 0001193125-26-119047 · ownership.xml · derivative · entry 2

KURIYEL RALF · CIK 0001733143 · Senior VP, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,669

Underlying: Common Stock · 5,669 shares

Expires 2036-03-05

F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

Read SEC document
March 05, 2026 Filed Mar 23, 2026 16:00 UTC
KURIYEL RALFSenior VP, R&D
GrantCommon Stock 5,284 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-119047 · ownership.xml · nonDerivative · entry 1

KURIYEL RALF · CIK 0001733143 · Senior VP, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,062

F1 · shares: Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
March 05, 2026 Filed Mar 23, 2026 15:53 UTC
Loeillot OlivierChief Executive Officer
GrantStock Option (Right to Buy) · Derivative 25,890 $0.00 Strike: $141.91 $0.00
Disclosure

SEC source: 0001193125-26-119036 · ownership.xml · derivative · entry 2

Loeillot Olivier · CIK 0001995525 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,890

Underlying: Common Stock · 25,890 shares

Expires 2036-03-05

F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

Read SEC document
March 05, 2026 Filed Mar 23, 2026 15:53 UTC
Loeillot OlivierChief Executive Officer
GrantCommon Stock 24,134 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-119036 · ownership.xml · nonDerivative · entry 1

Loeillot Olivier · CIK 0001995525 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,078

F1 · shares: Mr. Loeillot was awarded 24,134 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Read SEC document
March 05, 2026 Filed Mar 23, 2026 15:53 UTC
Bylund JamesChief Operating Officer
GrantStock Option (Right to Buy) · Derivative 8,315 $0.00 Strike: $141.91 $0.00
Disclosure

SEC source: 0001193125-26-119034 · ownership.xml · derivative · entry 2

Bylund James · CIK 0001849642 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,315

Underlying: Common Stock · 8,315 shares

Expires 2036-03-05

F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.